DEERFIELD, Ill., May 1, 2013 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper , et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535, the judge granted Takeda's motion for non-suit. The ruling nullifies the jury's April 26 verdict, which had awarded plaintiffs $6.5 million in damages. The trial began in February.
"We have empathy for Mr. Cooper and his family, but agree with the court's finding. In granting the motion, the judge ruled that the plaintiffs failed to offer any reliable evidence that Mr. Cooper's disease was caused by ACTOS (pioglitazone HC1)," said Kenneth D. Greisman , senior vice president, general counsel, Takeda Pharmaceuticals U.S.A., Inc.
Takeda is confident in the therapeutic benefits of ACTOS and its importance as a treatment for type 2 diabetes.
"Patient safety is a critical priority for Takeda," said Greisman. "We plan to vigorously defend the company against future lawsuits involving ACTOS."
Indication for ACTOS
ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 "juvenile" diabetes or diabetic ketoacidosis (increased ketones in blood or urine).
Important Safety Information
WARNING: HEART FAILURE
ACTOS can cause or worsen heart failure. ACTOS can cause the body to keep extra fluid (fluid retention), which leads to swelling (edema) and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. Heart failure means the heart does not pump blood well enough. Patients should not take ACTOS if they have severe heart failure. If patients have heart failure with symptoms such as shortness of breath or swelling
|SOURCE Takeda Pharmaceuticals U.S.A., Inc.|
Copyright©2012 PR Newswire.
All rights reserved